AG˹ٷ

STOCK TITAN

[Form 4] Jupiter Neurosciences, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Form 4 filing overview (JUNS � 7 July 2025)

CFO & Secretary Saleem Elmasri reported two equity-compensation transactions:

  • 66,293 common shares received on 06/02/2025 following the vesting of previously granted restricted stock units when the IPO lock-up expired (Transaction Code M, $0 exercise price). Direct ownership after the conversion stands at 66,239 shares.
  • Grant of 102,128 stock options on 07/02/2025 at an exercise price of $1.19 per share (Transaction Code A). The options begin vesting on 07/02/2025 in three equal annual installments and expire on 07/01/2035.

No open-market purchases or sales were disclosed; all activity reflects routine equity compensation. While the additional shares and options slightly increase potential dilution, they also raise insider ownership, better aligning management and shareholder interests.

Panoramica della presentazione del Modulo 4 (JUNS � 7 luglio 2025)

Il CFO e Segretario Saleem Elmasri ha comunicato due operazioni di compensazione azionaria:

  • 66.293 azioni ordinarie ricevute il 02/06/2025 a seguito del consolidamento di unità azionarie vincolate precedentemente assegnate, alla scadenza del periodo di lock-up post-IPO (Codice transazione M, prezzo di esercizio $0). La proprietà diretta dopo la conversione è pari a 66.239 azioni.
  • Concessione di 102.128 opzioni su azioni il 02/07/2025 con un prezzo di esercizio di $1,19 per azione (Codice transazione A). Le opzioni iniziano a maturare il 02/07/2025 in tre rate annuali uguali e scadono il 01/07/2035.

Non sono stati segnalati acquisti o vendite sul mercato aperto; tutta l’attività riflette la normale compensazione azionaria. Sebbene le azioni e opzioni aggiuntive aumentino leggermente la potenziale diluizione, incrementano anche la partecipazione degli insider, allineando meglio gli interessi del management e degli azionisti.

Resumen de la presentación del Formulario 4 (JUNS � 7 de julio de 2025)

El CFO y Secretario Saleem Elmasri reportó dos transacciones de compensación en acciones:

  • 66,293 acciones comunes recibidas el 02/06/2025 tras la consolidación de unidades de acciones restringidas previamente otorgadas al vencimiento del período de bloqueo tras la IPO (Código de transacción M, precio de ejercicio $0). La propiedad directa después de la conversión es de 66,239 acciones.
  • Otorgamiento de 102,128 opciones sobre acciones el 02/07/2025 con un precio de ejercicio de $1.19 por acción (Código de transacción A). Las opciones comienzan a consolidarse el 02/07/2025 en tres cuotas anuales iguales y vencen el 01/07/2035.

No se divulgaron compras ni ventas en el mercado abierto; toda la actividad corresponde a compensación de acciones habitual. Aunque las acciones y opciones adicionales aumentan ligeramente la posible dilución, también incrementan la propiedad de los insiders, alineando mejor los intereses de la dirección y los accionistas.

Form 4 제출 개요 (JUNS � 2025� 7� 7�)

CFO � 비서� Saleem Elmasri가 � 건의 주식 보상 거래� 보고했습니다:

  • 66,293 보통�가 2025� 6� 2� 기존� 부여된 제한 주식 단위� 권리 확정� 따라 IPO 락업 기간 만료 � 수령�(거래 코드 M, 행사가� $0). 전환 � 직접 소유 주식 수는 66,239�입니�.
  • 102,128 스톡옵션 부�가 2025� 7� 2� 주당 $1.19 행사가격으� 이루어짐(거래 코드 A). 옵션은 2025� 7� 2일부� 3년간 매년 동일� 비율� 권리 확정되며, 만료일은 2035� 7� 1일입니다.

공개 시장에서� 매수 또는 매도 내역은 없으�, 모든 거래� 일상적인 주식 보상 활동� 반영합니�. 추가� 주식� 옵션은 희석 가능성� 다소 높이지�, 내부� 지분도 증가시켜 경영진과 주주 � 이해관계를 더욱 � 일치시킵니다.

Présentation du dépôt du formulaire 4 (JUNS � 7 juillet 2025)

Le CFO et secrétaire Saleem Elmasri a rapporté deux opérations de rémunération en actions :

  • 66 293 actions ordinaires reçues le 02/06/2025 suite à l'acquisition de unités d'actions restreintes précédemment attribuées à l'expiration de la période de blocage post-introduction en bourse (code transaction M, prix d'exercice de 0 $). La propriété directe après conversion s'élève à 66 239 actions.
  • Attribution de 102 128 options d'achat d'actions le 02/07/2025 à un prix d'exercice de 1,19 $ par action (code transaction A). Les options commencent à s'acquérir le 02/07/2025 en trois versements annuels égaux et expirent le 01/07/2035.

Aucun achat ou vente sur le marché ouvert n'a été divulgué ; toutes les opérations reflètent une rémunération en actions habituelle. Bien que les actions et options supplémentaires augmentent légèrement la dilution potentielle, elles renforcent également la détention des initiés, alignant mieux les intérêts de la direction et des actionnaires.

Übersicht der Form 4 Einreichung (JUNS � 7. Juli 2025)

CFO & Sekretär Saleem Elmasri meldete zwei Transaktionen im Bereich Aktienvergütung:

  • 66.293 Stammaktien erhalten am 02.06.2025 nach der Vesting-Periode zuvor gewährter Restricted Stock Units bei Ablauf der IPO-Lock-up-Periode (Transaktionscode M, Ausübungspreis 0 $). Der direkte Besitz nach der Umwandlung beträgt 66.239 Aktien.
  • Gewährung von 102.128 Aktienoptionen am 02.07.2025 zu einem Ausübungspreis von 1,19 $ pro Aktie (Transaktionscode A). Die Optionen beginnen am 02.07.2025 in drei gleichen jährlichen Tranchen zu vesten und laufen am 01.07.2035 ab.

Es wurden keine Käufe oder Verkäufe am offenen Markt gemeldet; alle Aktivitäten spiegeln routinemäßige Aktienvergütung wider. Obwohl die zusätzlichen Aktien und Optionen die potenzielle Verwässerung leicht erhöhen, steigern sie auch den Insiderbesitz und bringen die Interessen von Management und Aktionären besser in Einklang.

Positive
  • CFO ownership increases by 66,293 shares, enhancing management–shareholder alignment.
  • Option grant vests over three years, encouraging medium-term performance and retention.
Negative
  • Issuance of 66,293 shares and 102,128 options adds incremental dilution to existing shareholders.
  • No open-market purchase; the insider did not commit personal capital, limiting bullish signaling value.

Insights

TL;DR: Routine equity awards; neutral share-dilution, modest alignment benefit.

The filing shows compensation-related share issuance and option grant to the CFO. Because the shares come from previously disclosed RSUs and the options carry an exercise price above zero, the immediate cash impact is nil. Potential dilution (�168k shares/options) is immaterial relative to typical micro-cap floats, and no market-priced buying or selling signal is present. Overall, the disclosure is operationally neutral but confirms management retention incentives.

TL;DR: Standard incentive structure; improves alignment, limited governance concern.

The RSU conversion followed the IPO lock-up, a standard post-listing practice. The three-year vesting schedule on the new option grant encourages medium-term value creation and talent retention. No red flags—such as accelerated vesting, unusually low strike price, or immediate sales—appear. From a governance standpoint, the transactions are typical and transparent, producing a neutral impact on shareholder rights.

Panoramica della presentazione del Modulo 4 (JUNS � 7 luglio 2025)

Il CFO e Segretario Saleem Elmasri ha comunicato due operazioni di compensazione azionaria:

  • 66.293 azioni ordinarie ricevute il 02/06/2025 a seguito del consolidamento di unità azionarie vincolate precedentemente assegnate, alla scadenza del periodo di lock-up post-IPO (Codice transazione M, prezzo di esercizio $0). La proprietà diretta dopo la conversione è pari a 66.239 azioni.
  • Concessione di 102.128 opzioni su azioni il 02/07/2025 con un prezzo di esercizio di $1,19 per azione (Codice transazione A). Le opzioni iniziano a maturare il 02/07/2025 in tre rate annuali uguali e scadono il 01/07/2035.

Non sono stati segnalati acquisti o vendite sul mercato aperto; tutta l’attività riflette la normale compensazione azionaria. Sebbene le azioni e opzioni aggiuntive aumentino leggermente la potenziale diluizione, incrementano anche la partecipazione degli insider, allineando meglio gli interessi del management e degli azionisti.

Resumen de la presentación del Formulario 4 (JUNS � 7 de julio de 2025)

El CFO y Secretario Saleem Elmasri reportó dos transacciones de compensación en acciones:

  • 66,293 acciones comunes recibidas el 02/06/2025 tras la consolidación de unidades de acciones restringidas previamente otorgadas al vencimiento del período de bloqueo tras la IPO (Código de transacción M, precio de ejercicio $0). La propiedad directa después de la conversión es de 66,239 acciones.
  • Otorgamiento de 102,128 opciones sobre acciones el 02/07/2025 con un precio de ejercicio de $1.19 por acción (Código de transacción A). Las opciones comienzan a consolidarse el 02/07/2025 en tres cuotas anuales iguales y vencen el 01/07/2035.

No se divulgaron compras ni ventas en el mercado abierto; toda la actividad corresponde a compensación de acciones habitual. Aunque las acciones y opciones adicionales aumentan ligeramente la posible dilución, también incrementan la propiedad de los insiders, alineando mejor los intereses de la dirección y los accionistas.

Form 4 제출 개요 (JUNS � 2025� 7� 7�)

CFO � 비서� Saleem Elmasri가 � 건의 주식 보상 거래� 보고했습니다:

  • 66,293 보통�가 2025� 6� 2� 기존� 부여된 제한 주식 단위� 권리 확정� 따라 IPO 락업 기간 만료 � 수령�(거래 코드 M, 행사가� $0). 전환 � 직접 소유 주식 수는 66,239�입니�.
  • 102,128 스톡옵션 부�가 2025� 7� 2� 주당 $1.19 행사가격으� 이루어짐(거래 코드 A). 옵션은 2025� 7� 2일부� 3년간 매년 동일� 비율� 권리 확정되며, 만료일은 2035� 7� 1일입니다.

공개 시장에서� 매수 또는 매도 내역은 없으�, 모든 거래� 일상적인 주식 보상 활동� 반영합니�. 추가� 주식� 옵션은 희석 가능성� 다소 높이지�, 내부� 지분도 증가시켜 경영진과 주주 � 이해관계를 더욱 � 일치시킵니다.

Présentation du dépôt du formulaire 4 (JUNS � 7 juillet 2025)

Le CFO et secrétaire Saleem Elmasri a rapporté deux opérations de rémunération en actions :

  • 66 293 actions ordinaires reçues le 02/06/2025 suite à l'acquisition de unités d'actions restreintes précédemment attribuées à l'expiration de la période de blocage post-introduction en bourse (code transaction M, prix d'exercice de 0 $). La propriété directe après conversion s'élève à 66 239 actions.
  • Attribution de 102 128 options d'achat d'actions le 02/07/2025 à un prix d'exercice de 1,19 $ par action (code transaction A). Les options commencent à s'acquérir le 02/07/2025 en trois versements annuels égaux et expirent le 01/07/2035.

Aucun achat ou vente sur le marché ouvert n'a été divulgué ; toutes les opérations reflètent une rémunération en actions habituelle. Bien que les actions et options supplémentaires augmentent légèrement la dilution potentielle, elles renforcent également la détention des initiés, alignant mieux les intérêts de la direction et des actionnaires.

Übersicht der Form 4 Einreichung (JUNS � 7. Juli 2025)

CFO & Sekretär Saleem Elmasri meldete zwei Transaktionen im Bereich Aktienvergütung:

  • 66.293 Stammaktien erhalten am 02.06.2025 nach der Vesting-Periode zuvor gewährter Restricted Stock Units bei Ablauf der IPO-Lock-up-Periode (Transaktionscode M, Ausübungspreis 0 $). Der direkte Besitz nach der Umwandlung beträgt 66.239 Aktien.
  • Gewährung von 102.128 Aktienoptionen am 02.07.2025 zu einem Ausübungspreis von 1,19 $ pro Aktie (Transaktionscode A). Die Optionen beginnen am 02.07.2025 in drei gleichen jährlichen Tranchen zu vesten und laufen am 01.07.2035 ab.

Es wurden keine Käufe oder Verkäufe am offenen Markt gemeldet; alle Aktivitäten spiegeln routinemäßige Aktienvergütung wider. Obwohl die zusätzlichen Aktien und Optionen die potenzielle Verwässerung leicht erhöhen, steigern sie auch den Insiderbesitz und bringen die Interessen von Management und Aktionären besser in Einklang.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Silva Alison D.

(Last) (First) (Middle)
C/O JUPITER NEUROSCIENCES, INC.
1001 NORTH US HYWAY 1, SUITE 504

(Street)
JUPITER FL 33477

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
JUPITER NEUROSCIENCES, INC. [ JUNS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Pres + Chief Business Officer
3. Date of Earliest Transaction (Month/Day/Year)
07/02/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $1.19 07/02/2025 A 255,320 07/02/2025(1) 07/01/2035 Common Stock 255,320 (1) 255,320 D
Explanation of Responses:
1. The options were granted under the Issuer's 2023 Equity Incentive Plan as a discretionary bonus for services rendered during fiscal 2024. The options vest in three equal installments over a three (3) year, beginning on July 2, 2025.
/s/ Alison Silva 07/07/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Jupiter Neurosciences (JUNS) shares did the CFO acquire?

Saleem Elmasri received 66,293 common shares from vested RSUs.

What is the exercise price of the newly granted JUNS stock options?

The 102,128 options have an exercise price of $1.19 per share.

When do the CFO’s new options begin vesting?

They start vesting on July 2, 2025 in three equal annual installments.

Did the filing report any insider sales of JUNS stock?

No sales were reported; all disclosed transactions were acquisitions or grants.

What is the CFO’s total direct share ownership after the transactions?

Direct ownership stands at 66,239 common shares, plus the 102,128 unexercised options.
JUPITER NEUROSCIENCES, INC.

NASDAQ:JUNS

JUNS Rankings

JUNS Latest News

JUNS Latest SEC Filings

JUNS Stock Data

39.39M
14.00M
54.21%
0.05%
0.34%
Biotechnology
Pharmaceutical Preparations
United States
JUPITER